Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Ospemifene appears to produce significant improvements in bladder wall thickness and vaginal dryness, as well as reductions in the number of episodes of nocturia and urgency, among others, in women with vulvovaginal atrophy (VVA) and overactive bladder (OAB) symptoms refractory to β3-agonists or antimuscarinic drugs, a study has shown.
About two in three men with prostate cancer are at increased cardiovascular (CV) risk, suggests a recent study. A positive association exists between a plan to use androgen deprivation therapy and baseline CV risk factors, but such link is explained by confounding factors.
Mirabegron add-on therapy is both safe and effective in the treatment of men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia, according to the results of a randomized, phase IV study.
Protein supplements do not have any effect on semen quality characteristics of healthy men, a study has found.
Use of oral vitamin D does not result in reduced urgency or mixed urinary incontinence (UI) progression in women, a study reports.
Platinum-based neoadjuvant chemotherapy appears to be beneficial in patients with bulky regional lymph node metastases from penile cancer, with nearly 50 percent responding to treatment and about 16 percent achieving a pathological complete response, results of a systematic review and meta-analysis have shown.
Children with pyelonephritis prescribed a short course or prolonged course of antibiotics had comparable rates of treatment failure, according to a retrospective, observational study.
Special Reports
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.
An electronic surveillance tool generated better compliance and satisfaction rates than standard in-person care among men with stage 1 testicular cancer, according to the interim results of the WATChmAN* trial presented at ASCO GU 2020.
While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).
The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.
